Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2007; 28(01): 7-13
DOI: 10.1055/s-0041-1733197
Original Article

Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer : A Retrospective Study

Shekhar Sharma
Department of Surgical Oncology, AIMS, Edapally, Ernakulam - 682026, India
,
D K Vijaykumar
Department of Surgical Oncology, AIMS, Edapally, Ernakulam - 682026, India
,
K Chitrathara
Department of Surgical Oncology, AIMS, Edapally, Ernakulam - 682026, India
,
Altaf GAUHAR Haji
Department of Surgical Oncology, AIMS, Edapally, Ernakulam - 682026, India
,
Robin C George
Department of Surgical Oncology, AIMS, Edapally, Ernakulam - 682026, India
,
K Pavithran
Department of Medical Oncology, AIMS, Edapally, Ernakulam - 682026, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
23 March 2022

© 2007. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Deppe G, Baumann P. Advances in ovarian cancer chemotherapy. Current Opin Oncol 2000;12:481-91.
  • 2 Griffiths CT. Surgical resection of tumour bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101– 4.
  • 3 Thingpen T. The if and when of surgical debulking for ovarian cancer. N Engl J Med 2004;351(24):2544- 46.
  • 4 Vergote I, Gorp TV, Amant F, Neven P, Berteloot P. Neoadjuvant chemotherapy for ovarian cancer. Oncology 2005;19(12):1615-22.
  • 5 Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002;20:1248–59.
  • 6 Hoskins WJ, Bundy BN, Thigpen JT, et al. The influence of cytoreductive surgery on recurrencefree interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159–166.
  • 7 Gadducci A, Sartori E, Maggino T, et al. Analysis of failures after negative second-look in patients with advanced ovarian cancer: An Italian multicenter study. Gynecol Oncol 1998;68:150–55.
  • 8 Pecorelli S, Odicino F, Favalli G. Ovarian cancer: Best timing and applications of debulking surgery. Ann Oncol 2000;11(suppl 3):141–44.
  • 9 Kuhn W, Rutke S, Spathe K, et al. Neoadjuvant chemotherapy followed by tumour debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 2001;92:2585–91.
  • 10 Wils J, Blijham G, Naus A, et al. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 1986;4:1068–73.
  • 11 Neijt JP, ten Bokkel Huinink WW, et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 1987;5:1157–68.
  • 12 Lawton FG, Redman CW, Luesley DM, et al. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet Gynecol 1989;73:61–65.
  • 13 Ng LW, Rubin SC, Hoskins WJ, et al. Aggressive chemosurgical debulking in patients with advanced ovarian cancer. Gynecol Oncol 1990; 38: 358–63.
  • 14 Jacob JH, Gershenson DM, Morris M, et al. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 1991;42:146–50.
  • 15 Lim JT, Green JA. Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. Clin Oncol (R Coll Radiol) 1993;5:198–202.
  • 16 Redman CW, Warwick J, Luesley DM, et al. Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynaecol 1994;101:142–146.
  • 17 van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after NACT on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629–34.
  • 18 Surwit E, Childers J, Atlas I, et al. Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 1996;6:356–61.
  • 19 Schwartz PE, Rutherford TJ, Chambers JT, et al. Neoadjuvant chemotherapy for advanced ovarian cancer: Long-term survival. Gynecol Oncol 1999;72:93–99.
  • 20 Huober J, Meyer A, Wagner U, et al. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. J Cancer Res Clin Oncol 2002;128:153–160.
  • 21 Kayikçioglu F, Kose MF, Boran N, et al. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 2001;11:466–470.
  • 22 Ansquer Y, Leblanc E, Clough K, et al: Neoadjuvant chemotherapy for unresectable ovarian carcinoma: A French multicenter study. Cancer 2001;91:2329–34.
  • 23 Vrscaj MU, Rakar S. Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: A retrospective case-control study. Eur J Gynaecol Oncol 2002;23:405–10.
  • 24 Ushijima K, Ota S, Komai K, et al. Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer. Int Sur 2002;87:185-90.
  • 25 Fanfani F, Ferrandina G, Corrado G, Fagotti A, Zakut HV, Mancuso S, et al. Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIC ovarian cancer patients. Oncology 2003;65(4):316-22.
  • 26 Shibata K, Kikkawa F, Mika M, et al. Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: Survival benefit and prognostic factors. Int J Gynecol Cancer 2003;13(5):587-92.
  • 27 Morice P, Dubernard G, Rey A, et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. Am Coll Surg 2003;197(6):955-63.
  • 28 Mazzeo F, Beliere M, Kerger J, et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol 2003;90:163-69.
  • 29 Chambers JT, Chambers SK, Voynick IM, et al. Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol Oncol 1990;37:327–31.
  • 30 Pestasides D, Farmakis D, Koumarianou A. The role of neoadjuvant chemotherapy in the treatment of advanced ovarian cancer. Onoclogy 2005;68:64-70.
  • 31 Chan YM, Ng TY, Ngan HY, Wong LC: Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: A prospective longitudinal study. Gynecol Oncol 2003;88:9–16.
  • 32 Bristow RE, Eisenhauer EL,Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 2007;104(2);480-90.
  • 33 Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2006;103(3):1070-6.
  • 34 Deo SVS, Goyal H, Shukla NK, et al. Neoadjuvant chemotherapy followed by surgical cytoreduction in advanced epithelial ovarian cancer. Ind J Cancer 2006;43(3):117-20.